| Costs of skin and skin structure infections due to Staphylococcus aureus: an analysis of managed-care claims. | |
| | |
MedLine Citation:
|
PMID: 18759996 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: The incidence of skin and skin structure infections (SSSIs) due to Staphylococcus aureus (SA) is increasing. The objective of this study was to assess the costs of a treatment episode for SA-SSSIs. METHODS: This retrospective analysis used a managed-care claims database to assess the duration and costs of incident SA-SSSI episodes treated with selected antibiotics (i.v. vancomycin, oral linezolid, and daptomycin, termed 'study antibiotics'). Patients were included if they had an ICD-9-CM diagnosis of an SSSI and SA between January 1, 2002 and December 31, 2005. Treatment episodes began on the date of the first antibiotic and ended when the patient had fourteen consecutive days without a study antibiotic or SSSI hospitalization. Costs, represented by health plan payments for SSSIs and overall, were updated to 2005 US dollars. A generalized linear model (GLM) assessed predictors of costs. RESULTS: A total of 1997 patients met the selection criteria. Mean (+/- SD) age was 46.3 (+/- 12.6) years and 55.9% of patients were male. Average episode length was 24 days, and over 95% of patients received i.v. vancomycin or oral linezolid as their initial study antibiotic. Patients remained on study antibiotics for an average of 16.4 days, and only 5% of patients were switched to another study antibiotic. Mean (+/- SD) overall episode costs were $8865 (+/- $20,003), primarily composed of inpatient and outpatient medical services. Treatment failure (i.e., study antibiotic switching or hospitalization), younger age, a diagnosis of bacteremia, osteomyelitis, or multiple complications during the episode, treatment with daptomycin, and greater Charlson co-morbidity score were significant positive predictors of overall costs. Alternatively, treatment with oral linezolid and hospitalization before the start of the outpatient treatment episode were significant negative predictors of overall costs. Mean (+/- SD) SSSI-related costs were $4551 (+/- $11,058). LIMITATIONS: Medical charts and laboratory test results were not available to confirm SSSI and SA diagnoses, and no information was available regarding antibiotics received in the inpatient setting. CONCLUSIONS: The costs of treating SA-SSSIs are substantial and vary by failure rates, co-morbidities, and type of antibiotic therapy. |
| | |
Authors:
|
Jeno P Marton; Juliana L Jackel; Robyn T Carson; Constance D Rothermel; Mark Friedman; Joseph Menzin |
Related Documents
:
|
8565166 - Cost-effectiveness of implantable defibrillator as first-choice therapy versus electrop... 9736126 - Clinical predictors easily obtained at presentation predict resource utilization in uns... 15897166 - Systemic treatment for moderate to severe psoriasis: estimates of failure rates and dir... 12022316 - Cost of joint replacement surgery for osteoarthritis: the patients' perspective. 1984586 - Venous ulceration: factors influencing recurrence after standard surgical procedures. 11347826 - Suprascapular neuropathy. variability in the diagnosis, treatment, and outcome. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2008-08-28 |
Journal Detail:
|
Title: Current medical research and opinion Volume: 24 ISSN: 1473-4877 ISO Abbreviation: Curr Med Res Opin Publication Date: 2008 Oct |
Date Detail:
|
Created Date: 2008-10-24 Completed Date: 2009-01-23 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0351014 Medline TA: Curr Med Res Opin Country: England |
Other Details:
|
Languages: eng Pagination: 2821-8 Citation Subset: IM |
Affiliation:
|
Pfizer Inc., New York, NY, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Anti-Bacterial Agents / agonists*, therapeutic use Costs and Cost Analysis Female Hospitalization / economics* Humans Insurance Claim Review Male Middle Aged Models, Theoretical* Retrospective Studies Staphylococcal Skin Infections / drug therapy, economics* Staphylococcus aureus* |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Bacterial Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Surveillance study of the susceptibility of Haemophilus influenzae to various antibacterial agents i...
Next Document: Post-fracture management of patients with hip fracture: a perspective.